ABVC BioPharma logo
ABVC BioPharma
ABVC | NASDAQ
Chart Builder DCF Calculator
$0.94
+$0.03 (+3.30%)
At close: Nov 16, 2026, 4:00 PM ET
$0.96
+$0.02 (+2.00%)
After-hours: Nov 16, 2026, 7:28 PM ET

ABVC BioPharma Company Profile

Company profile explained

Company Profile

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

Key Executives

Name Position
Uttam Yashwant Patil Chief Executive Officer & Interim Chief Financial Officer
Eugene Jiang Chairman & Chief Business Officer
Tsung-Shann Jiang Chief Scientific Officer, Chief Strategy Officer & Director

Latest SEC Filings

Date Type Title
Sep 29, 2026 DEF 14A Filing
Sep 11, 2026 PRER14A Filing
Aug 27, 2026 8-K Current Report
Aug 25, 2026 PRER14A Filing
Aug 17, 2026 424B4 Filing
Aug 17, 2026 424B4 Filing
Aug 17, 2026 424B4 Filing
Aug 17, 2026 424B4 Filing
Aug 12, 2026 PRER14A Filing
Aug 12, 2026 10-Q Quarterly Report
View All SEC Filings ➞
ABVC BioPharma
ABVC BioPharma logo
Country United States
IPO Date Nov 10, 2004
Industry Biotechnology
Sector Healthcare
Employees 18
CEO Uttam Yashwant Patil

Contact Details

44370 Old Warm Springs Boulevard Fremont, California 94538 United States

Stock Details

Ticker Symbol ABVC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001173313
CUSIP Number 00091F304
ISIN Number US00091F3047
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.